Plural activating optical change toothpastes, stimuli and elements

Details for Australian Patent Application No. 2005254053 (hide)

Owner Segan Industries, Inc.

Inventors Ribi, Hans O.

Agent Pizzeys

Pub. Number AU-A-2005254053

PCT Pub. Number WO2005/123023

Priority 60/579,060 10.06.04 US

Filing date 10 June 2005

Wipo publication date 29 December 2005

International Classifications

A61K 8/11 (2006.01) Cosmetics or similar toilet preparations - Encapsulated compositions

A61K 8/22 (2006.01) Cosmetics or similar toilet preparations

A61K 8/26 (2006.01) Cosmetics or similar toilet preparations

A61K 8/27 (2006.01) Cosmetics or similar toilet preparations

A61K 8/362 (2006.01) Cosmetics or similar toilet preparations

A61K 8/49 (2006.01) Cosmetics or similar toilet preparations

A61K 8/66 (2006.01) Cosmetics or similar toilet preparations

A61K 49/00 (2006.01) Preparations for testing

A61Q 11/00 (2006.01) Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastes

Event Publications

11 January 2007 PCT application entered the National Phase

  PCT publication WO2005/123023 Priority application(s): WO2005/123023

23 April 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005254055-Topical compositions containing 5'-adenosine-diphosphate ribose

2005254044-Methods for treating conditions associated with MASP-2 dependent complement activation